Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and SRS in Breast Cancer Brain Metastases
NCT03449238Phase 2Recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Nov 2018
- Primary completion
- Dec 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in breast cancer, brain metastasis (BM), sponsored by Weill Cornell Medicine. Started Nov 2018; status: recruiting.
02
Drugs
03
Conditions
breast cancerbrain metastasis (BM)
Beyond the preview
Go deeper on NCT03449238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03449238.